nach oben

Erschienen in:

01.02.2014 | Original Contribution

The inhibitory activities of the edible green alga Capsosiphon fulvescens on rat lens aldose reductase and advanced glycation end products formation

verfasst von: Md. Nurul Islam, Sung Hwa Choi, Hye Eun Moon, Jin Ju Park, Hyun Ah Jung, Mi Hee Woo, Hee Chul Woo, Jae Sue Choi

Erschienen in: European Journal of Nutrition | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Accumulating evidence suggests that inhibitors of aldose reductase (AR) may prevent hyperglycemia-induced long-term complications in diabetes mellitus. In the present study, we evaluated the AR inhibitory potential of ethanolic (EtOH) extracts from 22 seaweed species.

Methods

AR inhibitory activities of the selected seaweed species were evaluated using the rat lens aldose reductase (RLAR) inhibitory assay.

Results

All extracts exhibited RLAR inhibitory activity, which ranged from 5.87 to 92.71 % at a concentration of 50 μg/mL. Since Capsosiphon fulvescens exhibited significant inhibitory potential and is a frequently used foodstuff, it was selected for a detailed investigation using RLAR and advanced glycation end products (AGE) formation inhibitory assays. Among the different solvent-soluble fractions, the CH₂Cl₂, EtOAc, and n-BuOH fractions showed promising RLAR and AGE formation inhibitory activities. Considering the AR inhibitory potential, CH₂Cl₂ and EtOAc fractions were selected for chromatographic separation and yielded 11 compounds in which capsofulvesin A, capsofulvesin B, and chalinasterol showed potential RLAR inhibitory activity with the respective IC₅₀ values of 52.53, 101.92, and 345.27 μM. Kinetic studies revealed that capsofulvesin A and chalinasterol exhibited mixed type inhibition, while capsofulvesin B exhibited noncompetitive inhibition. To our knowledge, this is the first report of AR inhibitory activity of the glycolipids capsofulvesin A and capsofulvesin B.

Conclusions

Our results clearly indicate the potential RLAR and AGE formation inhibitory activities of C. fulvescens as well as its isolated constituents, which could be further explored to develop therapeutic modalities for the treatment of diabetes and related complications.

Nathan DM (1993) Long-term complications of diabetes mellitus. N Engl J Med 328:1676––1685CrossRef

McCune LM, Johns T (2002) Antioxidant activity in medicinal plants associated with the symptoms of diabetes mellitus used by the indigenous peoples of the North America boreal forest. J Ethnopharmacol 82:197–––205CrossRef

Brownlee M (2005) The Pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615–––1625CrossRef

Scott JA, King GL (2004) Oxidative stress and antioxidant treatment in diabetes. Ann NY Acad Sci 1031:204–––213CrossRef

Wautier JL, Guillausseau PJ (2001) Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 27:535–––542

Aronson D (2003) Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 21:3–––12CrossRef

Ahmed N (2005) Advanced glycation endproducts—role in pathology of diabetic complications. Diabetes Res Clin Pract 67:3–––21CrossRef

Thomas MC, Baynes JW, Thorpe SR, Cooper ME (2005) The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets 6:453–––474CrossRef

Wada R, Yagihashi S (2005) Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Ann NY Acad Sci 1043:598–––604CrossRef

10.

Hiroyuki F, Tomohide Y, Kazunori O (2001) Efficacy and safety of Touchi extract, an α-glucosidase inhibitor derived from fermented soybeans, in non-insulin-dependent diabetic mellitus. J Nutr Biochem 12:351–––356CrossRef

11.

Fujisawa T, Ikegami H, Inoue K, Kawabata Y, Ogihara T (2005) Effect of two alpha-glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms. Metabolism 54:387–––390CrossRef

12.

Shobana S, Sreerama YN, Malleshi NG (2009) Composition and enzyme inhibitory properties of finger millet (Eleusine coracana L.) seed coat phenolics: mode of inhibition of α-glucosidase and pancreatic amylase. Food Chem 115:1268–––1273CrossRef

13.

Suryanarayana P, Kumar AP, Saraswat M, Petrash JM, Reddy GB (2004) Inhibition of aldose reductase by tannoid principles of Emblica officinalis: implications for the prevention of sugar cataract. Mol Vis 10:148–––154

14.

Fang Z, Jeong SY, Jung HA, Choi JS, Min BS, Woo MH (2012) Capsofulvesins A-C, cholinesterase inhibitors from Capsosiphon fulvescens. Chem Pharm Bull 60:1351–––1358CrossRef

15.

Fang Z, Jeong SY, Choi JS, Min BS, Min BK, Woo MH (2012) Cholinesterase inhibitory constituents from Capsosiphon fulvescens. Nat Prod Sci 18:233–––238

16.

Hayman S, Kinoshita JH (1965) Isolation and properties of lens aldose reductase. J Biol Chem 240:877–––882

17.

Vinson JA, Howard TB III (1996) Inhibition of protein glycation and advanced glycation end products by ascorbic acid and other vitamins and nutrients. J Nutr Biochem 7:659–––663CrossRef

18.

Cheng AY, Fantus IG (2005) Oral antihyperglycemic therapy for type 2 diabetes mellitus. Can Med Assoc J 172:213–––226CrossRef

19.

Chen SS, Paul B (2012) The potential of incretin-based therapies in type 1 diabetes. Drug Discov Today 17:89–––95CrossRef

20.

Ferrannini E, Solini A (2012) SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 8:495–––502CrossRef

21.

Resnick HE, Foster GL, Bardsley J, Ratner RE (2006) Achievement of American diabetes Association clinical practice recommendations among US adults with diabetes, 1999–2002: the national health and nutrition examination survey. Diabetes Care 29:531–––537CrossRef

22.

Hotta N, Kawamori R, Fukuda M, Shigeta Y (2012) Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy. Diabetes Med 29:1529–––1–533CrossRef

23.

Moon HE, Islam MN, Ahn BR, Chowdhury SS, Sohn HS, Jung HA, Choi JS (2011) Protein tyrosine phosphatase 1B and α-glucosidase inhibitory phlorotannins from edible brown algae, Ecklonia stolonifera and Eisenia bicyclis. Biosci Biotechnol Biochem 75:1472–––1480CrossRef

24.

Jin DQ, Li G, Kim JS, Yong CS, Kim JA, Huh K (2004) Preventive effects of Laminaria japonica aqueous extract on the oxidative stress and xanthine oxidase activity in streptozotocin-induced diabetic rat liver. Biol Pharm Bull 27:1037–––1040CrossRef

25.

Wang W, Okada Y, Shi H, Wang Y, Okuyama T (2005) Structures and aldose reductase inhibitory effects of bromophenols from the red alga Symphyocladia latiuscula. J Nat Prod 68:620–––622CrossRef

26.

Liu X, Li X, Gao L, Cui C, Li C, Li J, Wang B (2011) Extraction and PTP1B inhibitory activity of bromophenols from the marine red alga Symphyocladia latiuscula. Chin J Oceanol Limnol 29:686–––690CrossRef

27.

Cooper ME (1998) Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 352:213–––219CrossRef

28.

Marjorie D (2000) Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int 58:S3–––S12

29.

Moghaddam MS, Kumar AP, Reddy BG, Ghole VS (2005) Effect of Diabecon on sugar-induced lens opacity in organ culture: mechanism of action. J Ethnopharmacol 97:397–––403CrossRef

30.

Da Settimo F, Primofiore G, La Motta C, Sartini S, Taliani S, Simorini F, Marini AM, Lavecchia A, Novellino E, Boldrini E (2005) Naphtho[1,2-d]isothiazole acetic acid derivatives as a novel class of selective aldose reductase inhibitors. J Med Chem 48:6897–––6907CrossRef

31.

Da Settimo F, Primofiore G, Da Settimo A, La Motta C, Simorini F, Novellino E, Greco G, Lavecchia A, Boldrini F (2003) Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives. J Med Chem 46:1419–––1428CrossRef

32.

Alexiou P, Pegklidou K, Chatzopoulou M, Nicolaou I, Demopoulos VJ (2009) Aldose reductase enzyme and its implication to major health problems of the 21(st) century. Curr Med Chem 16:734–––752CrossRef

33.

El-Kabbani O, Carbone V, Darmanin C, Oka M, Mitschler A, Podjarny A, Schulze-Briese C, Chung RP (2005) Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity. J Med Chem 48:5536–––5542CrossRef

34.

Schemmel KE, Padiyara RS, D′Souza JJ (2010) Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. J Diabetes Complications 24:354–––360CrossRef

35.

Grimshaw CE, Lai CJ (1996) Oxidized aldose reductase: in vivo factor not in vitro artifact. Arch Biochem Biophys 327:89–––97CrossRef

36.

Bucala R, Cerami A (1992) Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 23:1–––34CrossRef

37.

Kalousova M, Zima T, Tesar V, Stipek S, Sulkova S (2004) Advanced glycation end products in clinical nephrology. Kidney Blood Press Res 27:18–––28CrossRef

38.

Peyroux J, Sternberg M (2006) Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes. Pathol Biol 54:405–––419CrossRef

39.

Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A (1986) Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232:1629–––1632CrossRef

40.

Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW (1994) Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 43:676–––683CrossRef

41.

Huijberts MSP, Wolffenbuttel BHR, Boudier HAJS, Crijns FRL, Kruseman CAN, Poitevin P, Levy B (1993) Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J Clin Invest 92:141–––1407CrossRef

42.

Birrell AM, Heffernan SJ, Kirwan P, McLennan S, Gillin AG, Yue DK (2002) The effects of aminoguanidine on renal changes in a baboon model of type 1 diabetes. J Diabetes Complications 16:301–––309CrossRef

43.

Asif M, Egan J, Vasan S, Jyothirmayi GN, Masurekar MR, Lopez S, Williams C, Torres RL, Wagle D, Ulrich P, Cerami A, Brines M, Regan TJ (2000) An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci USA 97:2809–––2813CrossRef

44.

Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit DKA, Thomas MC, Burns WC, Deemer EK, Thorpe SM, Cooper ME, Allen TJ (2004) Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 53:1813–––1823CrossRef

45.

Stitt A, Gardiner TA, Alderson NL, Canning P, Frizzell N, Duffy N, Boyle C, Januszewski AS, Chachich M, Baynes JW, Thorpe SR (2002) The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51:2826–––2832CrossRef

46.

Alkhalaf A, Klooster A, Oeveren VW, Achenbach U, Kleefstra N, Slingerland RJ, Mijnhout GS, Bilo HJG, Gans ROB, Navis GJ, Bakker SJL (2010) A double-blind, randomized, placebocontrolled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care 33:1598–––1601CrossRef

47.

Shetty AK, Rashmi R, Rajan MGR, Sambaiah K, Salimath PV (2004) Antidiabetic influence of quercetin in streptozotocin induced diabetic rats. Nutr Res 24:373–––381CrossRef

48.

Kato A, Yasuko H, Gotob H, Hollinsheadc J, Nashc RJ, Adachia I (2009) Inhibitory effect of rhetsinine isolated from Evodia rutaecarpa on aldose reductase activity. Phytomedicine 16:258–––261CrossRef

49.

Lee J, Kim NH, Nam WN, Lee YM, Jang DS, Kim YS, Nam SH, Seo EK, Yang MS, Kim JS (2010) Scopoletin from the flower buds of Magnolia fargesii inhibits protein glycation, aldose reductase, and cataractogenesis ex vivo. Arch Pharm Res 33:1317–––1323CrossRef

50.

Ha DT, Ngoc TM, Lee IS, Lee YM, Kim JS, Jung HJ, Lee SM, Na MK, Bae KH (2009) Inhibitors of aldose reductase and formation of advanced glycation end-products in Moutan Cortex (Paeonia suffruticosa). J Nat Prod 72:1465–––1470CrossRef

Titel: The inhibitory activities of the edible green alga Capsosiphon fulvescens on rat lens aldose reductase and advanced glycation end products formation
verfasst von: Md. Nurul Islam
Sung Hwa Choi
Hye Eun Moon
Jin Ju Park
Hyun Ah Jung
Mi Hee Woo
Hee Chul Woo
Jae Sue Choi
Publikationsdatum: 01.02.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nutrition / Ausgabe 1/2014
Print ISSN: 1436-6207
Elektronische ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-013-0521-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Absorption and isomerization of caffeoylquinic acids from different foods using ileostomist volunteers

Effects of high-tryptophan diet on pre- and postnatal development in rats: a morphological study

Daidzein, R-(+)equol and S-(−)equol inhibit the invasion of MDA-MB-231 breast cancer cells potentially via the down-regulation of matrix metalloproteinase-2

Positive muscle protein net balance and differential regulation of atrogene expression after resistance exercise and milk protein supplementation

Contribution of creatine to protein homeostasis in athletes after endurance and sprint running